Iktos is a French start-up company that develops a truly innovative and disruptive artificial intelligence technology for ligand-based de novo drug design, focusing on MPO (multi-parametric optimization). Our innovative algorithm is based on the state of the art deep learning models, called generative models, and enables to the design of new, druggable, and synthesizable molecules under the constraint of a given blueprint, with unprecedented speed and performance.
B2B
1 to 25
Funded
N/A
Scaling Up
2016
Pharmaceuticals
Information Technology and Services
Healthcare
Chemicals
Automated Virtual Lead Design
Drug Design
Production
Yes
Active
Machine Learning
Machine Perception
Knowledge Representation and Reasoning
N/A
Software
N/A
N/A
0
1
$16.6M
Company was founded 2016 and it took almost 7 years (Mar 2023) to raise first external round
Investors
Interested in researching Iktos?
We have plenty of data and we can help. Our deal sourcing platform can help you perform more research about Iktos
